Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Envoy Medical, Inc. (NASDAQ: COCH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a hearing health business focused on fully implanted hearing devices. Envoy Medical files reports and registration statements that describe its Esteem® fully implanted active middle ear implant (FI-AMEI), the investigational fully implanted Acclaim® cochlear implant, its financial condition, capital structure, and key risks.
Through its Forms 10-Q and 10-K, Envoy Medical presents detailed financial statements and management discussion of operations, including net revenues from the Esteem FI-AMEI and related components, research and development expenses tied to the Acclaim pivotal clinical trial, and general and administrative costs associated with operating as a public company. These periodic reports also discuss liquidity, capital resources, and risk factors relevant to investors evaluating COCH.
Current reports on Form 8-K capture material events such as FDA approval to expand the pivotal clinical trial for the fully implanted Acclaim cochlear implant to its final stage, notices and determinations related to Nasdaq listing requirements, equity and warrant financing transactions, and quarterly earnings announcements. Proxy materials on Schedule 14A outline shareholder proposals, including approvals related to warrant issuances under Nasdaq rules, and provide additional context on the company’s capital raising activities.
Envoy Medical has also filed registration statements on Form S-1 and Form S-3 covering offerings of Class A common stock, pre-funded warrants, and the resale of shares underlying private placement warrants. These documents describe the company as an emerging growth company and a smaller reporting company, and they summarize its business focus on fully implanted hearing technologies, including the Esteem FI-AMEI and the investigational Acclaim cochlear implant.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, such as key changes in revenues and expenses, updates on the Acclaim clinical trial, new financing arrangements, and material listing or regulatory developments. Users can quickly review Forms 10-K and 10-Q for an overview of Envoy Medical’s financial performance, scan 8-K filings for significant events, and examine registration statements and proxy materials for details on securities offerings and shareholder approvals, all with real-time updates from the SEC’s EDGAR system.
Envoy Medical, Inc. filed a Form S-1 for a primary, reasonable best efforts offering of Class A Common Stock and pre-funded warrants, with all net proceeds going to the company. The securities will be priced with investors and the placement agent based on market conditions, and pre-funded warrants are structured so investors do not exceed 4.99% or 9.99% ownership limits. Envoy had 28,934,960 shares of Common Stock outstanding as of December 15, 2025.
The company is a hearing health developer focused on its fully implanted Acclaim cochlear implant, which has FDA Breakthrough Device Designation and is in a pivotal clinical trial whose second stage was cleared by the FDA on October 3, 2025. Envoy reported net losses of $17.2 million for the nine months ended September 30, 2025 and has an accumulated deficit of $305.7 million, and its auditors have raised substantial doubt about its ability to continue as a going concern. Recent registered direct offerings in September and October 2025 raised about $6.5 million in gross proceeds, and the company faces Nasdaq compliance pressures related to both minimum market value of listed securities and minimum bid price.
Envoy Medical, Inc. is providing an updated investor presentation that its management may use, with possible modifications, in meetings with current and potential investors. The presentation is attached as Exhibit 99.1 and includes forward-looking statements, with related risks and uncertainties described in the presentation. This information is being furnished under Regulation FD and is not deemed filed or incorporated into other securities law filings unless specifically referenced.
Envoy Medical, Inc. director Mona Chetan Patel reported changes in her holdings on a Form 4. On 12/03/2025 she acquired 25,000 stock options, each with an exercise price of $0.813, exercisable starting 05/01/2026 and expiring 12/03/2035, covering 25,000 shares of Class A common stock. She also beneficially owns 20,000 shares of Class A common stock directly and holds 25,000 stock options with a $2.4 exercise price expiring 10/15/2033. The filing notes that options to purchase 6,250 shares vest on 10/15/2024, with the remaining 18,750 shares vesting pro rata on the 15th of each month for 36 months.
Envoy Medical, Inc. (COCH) reports that Nasdaq has notified the company its Class A common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, after trading below that level for 30 consecutive business days. The stock remains listed for now.
Envoy has 180 calendar days, until May 18, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. If it qualifies, the company may receive an additional 180‑day period and could use measures such as a reverse stock split to address the deficiency. Failure to regain or maintain compliance could lead to a Nasdaq delisting determination, which Envoy could appeal. The company states it intends to monitor its share price and consider available options.
Envoy Medical (COCH) filed its Q3 2025 10-Q, reporting net revenues of $42 thousand and an operating loss of $5.708 million. Net loss was $6.482 million, or $0.35 per share. Cash was $3.556 million as of September 30, 2025.
The company eliminated related-party debt via a satisfaction agreement, recording a $27.879 million capital contribution to additional paid-in capital and improving total stockholders’ deficit to $7.661 million. Management states that recurring losses and limited cash raise substantial doubt about the company’s ability to continue as a going concern.
During the quarter, Envoy completed a registered direct offering of 1,908,402 shares for gross proceeds of $2.5 million and issued 5,725,206 Investor Warrants, recognized as a liability measured at fair value. An at-the-market program added $414 thousand year-to-date. The FDA granted an IDE in October 2024 to begin a pivotal study of the fully implanted Acclaim cochlear implant, while the Esteem device continues to generate modest revenue.
Envoy Medical (COCH) furnished an Item 2.02 Form 8-K announcing it issued a press release with financial results for its third fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The disclosure is furnished, not filed, and is therefore not subject to Section 18 liabilities or incorporation by reference.
Envoy Medical (COCH) received a Nasdaq compliance extension. The Nasdaq Hearings Panel granted the company an exception to satisfy the $35 million market value of listed securities requirement through February 23, 2026.
The company must promptly notify the Panel of any significant events that could affect meeting the exception’s terms. Envoy was first notified of noncompliance on February 25, 2025, did not regain compliance within the 180-day cure period, and presented its case at a hearing on October 2, 2025. On October 27, 2025, it issued a press release announcing the Panel’s decision.
Envoy’s Class A common stock trades on Nasdaq under COCH, and its redeemable warrants under COCHW.
Envoy Medical called a special stockholders’ meeting on November 26, 2025 to approve, under Nasdaq Listing Rule 5635(d), the exercisability of newly issued warrants and the issuance of the Class A Common Stock underlying them. The warrants stem from a September 2025 financing: Private Warrants to purchase up to 5,725,206 shares at $1.31 and Placement Agent Warrants for 143,130 shares at $1.6375, plus additional placement agent warrants equal to 7.5% of Private Warrant exercises. These warrants become exercisable only after stockholder approval.
If all Private and Placement Agent Warrants are exercised, an additional 6,297,726 shares would be outstanding. The company states it would realize up to approximately $8.4 million in gross proceeds upon full exercise. Shares outstanding were 23,809,975 as of October 2, 2025. The Board unanimously recommends voting FOR both the Issuance Proposal and a potential meeting adjournment to solicit additional proxies. A voting agreement indicates the Taylor Parties, who beneficially own approximately 43.2%, will vote in favor of the issuance.
Envoy Medical, Inc. filed a resale Form S-1 registering up to 15,116,472 shares of Class A Common Stock for selling stockholders. These are issuable upon exercise of previously issued warrants: 5,725,206 September Private Placement Warrant shares at $1.31, 9,022,572 October Private Placement Warrant shares at $1.33, 143,130 September Placement Agent Warrant shares at $1.6375, and 225,564 October Placement Agent Warrant shares at $1.6625.
The company will not receive proceeds from share resales. If all warrants are exercised for cash, Envoy Medical would receive approximately $20.1 million. September Private Placement and Placement Agent Warrants become exercisable upon stockholder approval; the October Private Placement and Placement Agent Warrants were immediately exercisable and expire two years after the registration statement’s effective date, subject to outside dates in
Recent updates note completed Stage 1 implantation and activation of 10 patients in the pivotal Acclaim cochlear implant trial, with FDA approval to proceed to Stage 2 (adding 46 participants). The company also disclosed prior registered offerings in
Envoy Medical, Inc. entered into a financing in which it will sell 3,007,524 shares of Class A common stock in a registered direct offering at $1.33 per share, for expected gross proceeds of about $4.0 million before fees and expenses. At the same time, the company will issue Private Warrants in a concurrent private placement to purchase up to 9,022,572 additional shares at $1.33 per share, which could bring in about $12.0 million in additional gross proceeds if fully exercised in cash.
The Private Warrants are immediately exercisable and will expire two years after the resale registration for the warrant shares becomes effective. Envoy agreed to file a resale registration statement on Form S-1 within 30 days and to seek effectiveness within 90 days of closing. The company also granted H.C. Wainwright & Co. cash fees on the offering and warrant exercises and issued it Placement Agent Warrants for up to 225,564 shares at an exercise price of $1.6625 per share. Envoy plans to use the net proceeds for working capital and general corporate purposes.
FAQ
What is the current stock price of Envoy Medical (COCH)?
What is the market cap of Envoy Medical (COCH)?
